Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line study of dostarlimab plus niraparib with platinum chemotherapy in advanced non-mucinous epithelial ovarian cancer
MOH_2018-12-11_004840Phase 3Active, not recruiting
- Sponsor
- TESARO, Inc.
- Start
- Nov 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dostarlimab and niraparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by TESARO, Inc. Started Nov 2018; status: active, not recruiting.
02
Drugs
dostarlimabniraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2018-12-11_004840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-11_004840.